Who
Steve Elms
Director
Company insider
Files Form 4 as: Director and 10% owner, ADMA Biologics; Director, Marker Therapeutics; Director, Elevation Oncology; Director and 10% owner, Zosano Pharma; Director and 10% owner, Loxo Oncology; Director, Pernix Therapeutics Holdings; Director, Cidara Therapeutics; Director, Ambit Biosciences.
In numbers
- Trades disclosed
- 129
- Buys
- 6
- Sells
- 10
- Bought
- $11.2M
- Sold
- $55.5M
- Companies
- 9
- Companies where not an officer
- 9
- First trade
- 22 May 2008
- Last trade
- 6 Mar 2026
- Last filed
- 9 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Mar 2026filed 9 Mar 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Bought | $108K7,000 at $15.39 | filing |
| 6 Mar 2026filed 9 Mar 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Bought | $108K7,000 at $15.39 | filing |
| 5 Mar 2026filed 9 Mar 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Bought | $110K7,000 at $15.67 | filing |
| 5 Mar 2026filed 9 Mar 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Bought | $110K7,000 at $15.67 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Code A | —10,690 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,730 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,730 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Code A | —10,690 at $0.00 | filing |
| 17 Nov 2025filed 19 Nov 2025 | MRKR Marker Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,411 at $0.00 | filing |
| 17 Nov 2025filed 19 Nov 2025 | MRKR Marker Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —137,330 at $0.00 | filing |
| 23 Jul 2025filed 24 Jul 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code D | —31,238 at $0.00 | filing |
| 23 Jul 2025filed 24 Jul 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code D | —15,619 at $0.00 | filing |
| 23 Jul 2025filed 24 Jul 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code D | —31,238 at $0.00 | filing |
| 23 Jul 2025filed 24 Jul 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code D | —35,000 at $0.00 | filing |
| 23 Jul 2025filed 24 Jul 2025 | Elevation Oncologyoption or derivative | SEC FORM 4 Code D | —35,000 at $0.00 | filing |
| 16 Jun 2025filed 16 Jun 2025 | ADMA ADMA BiologicsBiotechnology | SEC FORM 4 Sold | $3.9M194,749 at $20.24 | filing |
| 13 Jun 2025filed 16 Jun 2025 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,000 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —53,837 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | ADMA ADMA Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,500 at $0.00 | filing |
News
Arcturus Therapeutics (NASDAQ:ARCT) & ADMA Biologics (NASDAQ:ADMA) Head-To-Head SurveyADMA · dailypolitical.com · 18 Oct 2026Analyzing Anika Therapeutics (NASDAQ:ANIK) & ADMA Biologics (NASDAQ:ADMA)ADMA · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Steve Elms; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.